Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Maternity
  4. Back
  5. Ultrasound
  6. Twin Pregnancy Ultrasound Guideline (330)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Twin Pregnancy Ultrasound Guideline (330)

Please report any inaccuracies or issues with this guideline using our online form

Gestational Age, Chorionicity and Amnionicity

Women should be offered a first trimester USS (< 14+0 weeks) to estimate gestational age and determine chorionicity and amnionicity.

Chorionicity and amnionicity should be determined by the number of placental masses, the presence of amniotic membranes and membrane thickness, the lambda or T-sign.

Clear nomenclature should be assigned e.g inferior and superior, or left and right, in a twin or triplet pregnancy to ensure consistency throughout pregnancy.

If a multiple pregnancy presents after 14+0 weeks then determination of chorionicity and amnionicity could also take into account discordant fetal sex if required.

If TAUSS views are poor because of a retroverted uterus or a high BMI, use a transvaginal ultrasound scan to determine chorionicity and amnionicity.

The largest baby should be used to calculate the estimated date of delivery for the pregnancy.

A photographic record should be placed in the patient’s hospital held records documenting the ultrasound appearance of the membrane attachment to the placenta and an electronic / hard drive record stored. Chorionicity must be checked by senior sonographer

If there is still doubt about the chorionicity, the woman should be referred to medical staff for chorionicity assessment without delay.

Following this if there is still doubt, the pregnancy should be managed as monochorionic until proved otherwise.

Screening

Referral should be made for counselling for antenatal screening for combined trisomy (21,18,13) following the diagnosis of a twin pregnancy (fetal medicine at QEUH, Day Care counselling midwife PRM, Screening midwife Clyde). This should ideally be prior to the 11+2 to 14+1 week scan.

The test of choice for twin pregnancies is first trimester combined screening. Every opportunity must be made to maximise the offer of first trimester combined screening. Chance results to be reported are:

  • a term chance of T21 and a term chance of T18/T13
  • a term chance of T21 only
  • a term chance of T18/T13 only

First trimester combined screening will be reported in a dichorionic twin pregnancy as a chance for each fetus whereas in a monochorionic twin pregnancy it will be reported as a chance per pregnancy.

Women who ‘miss’ or have unsuccessful first trimester screening for aneuploidy should be offered second trimester screening for T21. Chance results are reported as a pregnancy related chance that is not fetal specific.

Monochorionic Twins

Fetal ultrasound assessment should be performed every two weeks in uncomplicated monochorionic twins from 16+0 weeks onwards until delivery.

Scans at 16 and 20 weeks (detailed anomaly scan) should be performed by a medical sonographer. The detailed fetal anomaly scan should include extended cardiac views (5 standard views).

At every ultrasound, the following should be assessed and recorded:

  • liquor volume (LV) should be assessed in each sac and deepest vertical pool (DVP)
  • Umbilical artery pulsatility index (UAPI)*
  • Fetal bladders should be assessed.
  • Middle Cerebral Artery Peak Systolic Velocity (MCA PSV)

*See Umbilical Artery Pulsatility Index Chart

Increase the frequency of diagnostic monitoring for TTTS in the woman’s 2nd and 3rd trimester to at least weekly if there are concerns about differences between the babies’ amniotic fluid level (a difference in DVP depth of 4cm or more). Include Doppler assessment of the umbilical artery flow for each baby.

Refer for medical scan if LV DVP>8 cm or <2cm before 20 weeks or LV DVP >10cm or <2cm after 20 weeks. If abnormality confirmed discussion with fetal medicine at QEUH is indicated.

Staging of Twin-to-twin transfusion syndrome (TTTS)

Stage Description

I

II

III

IV

V

Poly/oligohydramnios with bladder of the donor still visible

Bladder of the donor no longer visible

Presence of either absent or reverse end-diastolic velocity of the umbilical artery, reverse flow in either twin

Hydrops in either twin

Demise of one or both twins prior to surgery

From 16+0 weeks fetal biometry (HC, AC and FL) should be assessed and abdominal circumference (AC) and Estimated fetal weight (EFW) recorded for each twin. The discordance in EFW should be calculated and documented in monochorionic twins at each visit:

([EFW larger fetus − EFW smaller fetus] ÷ EFW larger fetus) × 100

Increase diagnostic monitoring in the 2nd and 3rd trimesters to at least weekly, and include Doppler assessment of the umbilical artery flow for each baby, if there is an EFW discordance of 20% or more and/or the EFW of any of the babies is below the 10th centile for gestational age.

Refer women with a monochorionic twin pregnancy to a tertiary level fetal medicine centre if there is an EFW discordance of 25% or more and the EFW of either of the babies is below the 10th centile for gestational age because this is a clinically important indicator of selective fetal growth restriction.

Selective intrauterine growth restriction (growth discordance of >20%). Approximately 10-15 % of MCDA twins

Stage Description

I

II

III

Growth discordance but positive diastolic velocities in both fetal umbilical arteries.

Growth discordance with absent or reversed end-diastolic velocities (AREDV) in one or both fetuses.

Growth discordance with cyclical umbilical artery diastolic waveforms (positive followed by absent then reversed end-diastolic flow in a cyclical pattern over several minutes [intermittent AREDV; iAREDV]).

Offer weekly USS monitoring for TAPS from 16 weeks of pregnancy using middle cerebral artery peak systolic velocity (MCA-PSV) to women who pregnancies are complicated by:

  • feto-fetal transfusion syndrome that has been treated by fetoscopic laser therapy or
  • selective fetal growth restriction (defined by an EFW discordance of 25% or more and an EFW of any of the babies below the 10th centile for gestational age)

Aim for delivery between 36+0 and 36+6 for uncomplicated MCDA twins after which point continuing the pregnancy increases the risk of fetal death

For monochorionic monoamniotic twins birth should be planned between 32+0 and 33+6

Dichorionic Twins

Fetal anomaly scan can be performed by sonographer if there are no other obstetric reasons for a medical FAS.

Growth USS should be performed every 4 weeks from 24 weeks onwards. Estimated fetal weight, umbilical artery PI and deepest vertical pool of liquor should be measured at each visit.

Fetal weight discordance should be calculated for dichorionic twins:

([EFW larger fetus − EFW smaller fetus] ÷ EFW larger fetus) × 100

Increase monitoring in 2nd and 3rd trimesters to at least weekly, and include Doppler assessment of the umbilical artery flow for each baby if there is EFW discordance of 20% or more and/or the EFW of any of the babies is below the 10th centile for gestational age.

Refer women with a dichorionic twin pregnancy to a tertiary level fetal medicine centre if there is an EFW discordance of 25% or more and the EFW of any of the babies is below the 10th centile for gestational age because this is a clinically important indicator of selective fetal growth restriction.

Aim for delivery between 37+0 and 37+6 for uncomplicated DCDA twins as after this point continuing the pregnancy increases the risk of fetal death.

Appendix: Umbilical Artery Pulsatility Index (UAPI) Reference Chart

> 95th percentile is abnormal

Appendix: MONOCHORIONIC DIAMNIOTIC TWINS – antenatal appointments

(File in notes)

Monochorionic diamniotic twins - antenatal appointments - pdf

Appendix: DICHORIONIC DIAMNIOTIC TWINS –antenatal appointments

(File in notes)

Dichorionic diamniotic twins - antenatal appointments - pdf

Editorial Information

Last reviewed: 24/10/2023

Next review date: 31/10/2028

Author(s): Victoria Watson ST7 PRM, Donna Bean, Lead Sonographer Obstetrics and Gynaecology.

Version: 3

Approved By: Maternity Clinical Governance Group

Document Id: 330

References
  1. NICE [NG137. Twin and triplet pregnancy. 2019.
  2. Khalil A. ISUOG Practice Guidelines: role of ultrasound in twin pregnancy. Ultrasound in Obstetrics and Gynaecology. ISUOG. November 2015.
  3. NHS Fetal Anomaly Screening Programme (FASP). Public Health England. September 2019.